Allyx Therapeutics

• NCT06632990

  Phase 1, Active, not recruiting, 36 people, 9 Oct 2024

• Exploratory associations between APOE-ε4 carrier status and facial neuromuscular activity in cognitively intact adults: a cross-sectional surface electromyography study

  Consulting or advice, 23 Sept 2026

• Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial

  Consulting or advice, 12 Nov 2025

Sources: pubmed.ncbi.nlm.nih.gov